Cluster headache market

Q: Which is the major type segment in the market?

Episodic is the major type segment in the market. Read more

Cluster Headache Market, by Type (Episodic and Chronic), by Drug Type (Fast-acting Drugs, Long-term Drugs, and Short-term Drugs), by Route of Administration (Oral, Topical, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Oct 2021
CMI4709
192 Pages
Excel & Pdf
Pharmaceutical

Summary

A cluster headache (CH) is a rare type of headache. The attack lasts for 15 minutes to three hours, occurs daily or almost daily for weeks or months. The causes of cluster headache appears to be related to the body's sudden release of histamine (a chemical in the body that is released during an allergic reaction) or serotonin (a chemical produced by nerve cells) in the area of a nerve situated in the face called the trigeminal nerve. A problem may be involved in a small area at the base of the brain called the hypothalamus. Cluster headache can be triggered by alcohol and smoking cigarette, high altitudes, bright lights, exertion, heat, foods rich in nitrite, certain drugs, and cocaine.

Some types of acute treatment (oxygen, tripants, octreotide, and others), preventive treatment (calcium channel blockers, corticosteroids, lithium carbonate, and others), and surgery in severe cases can provide some pain relief.

The global cluster headache market is estimated to be valued at US$ 355.2 Million in 2021 and is expected to increase to US$ 550.1 Million by 2028, witnessing a CAGR of 6.4% over the forecast period (2021-2028).

Figure 1. Global Cluster Headache Market Value (US$ Mn) & Y-o-Y Growth (%)

Increasing prevalence of cluster headache patients with a positive family history is expected to drive the growth of the global cluster headache market.

Increasing prevalence of cluster headache patients with a positive family history is expected to drive the growth of the global cluster headache market. For instance, according to a research article published by BMC (Bio med central) in April 2020, a systematic review and meta-analysis was carried out in accordance with the guidelines for preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA- P). It was found that an estimated prevalence of CH patients with a family history was around 6.27% with an overall I² of 73%.

Cluster Headache Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 355.2 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	6.4%	2028 Value Projection:	US$ 550.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Episodic, Chronic By Drug Type: Fast-acting Drugs, Long-term Drugs, Short-term Drugs By Route of Administration: Oral, Topical, Intravenous, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.
Growth Drivers:	Increasing incidence and prevalence of CH Development of novel therapeutics for the treatment of CH Increasing global geriatric population
Restraints & Challenges:	Insufficient awareness among healthcare providers Unfavorable healthcare policies negatively impacting overall healthcare spending

Figure 2. Global Cluster Headache Market Share (%), By Region, 2021

Global Cluster Headache Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sector, which is majorly impacted by the COVID-19 pandemic.

The coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the medication used in treatment of CH disease manufactured by various companies across the regions such as North America, Europe, and Asia Pacific. Moreover, the production and supply of pharmaceutical products is also affected due to lockdown imposed globally during the COVID-19 pandemic. Moreover, screen time of people during COVID-19 has continued to increase due to public health measures imposed by the government to contain the pandemic, which will drive the global market for cluster headache.

Global Cluster Headache Market: Restraint

Insufficient awareness among healthcare providers and unfavorable healthcare policies negatively impacting overall healthcare spending is hampering the global cluster headache market.

Key Players

Major players operating in the global cluster headache market include Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.

Table of Content

*Browse 44 market data tables and 35 figures on "Cluster Headache Market” - Global forecast to 2028

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

The global cluster headache market size is estimated to be valued at US$ 355.2 Million in 2021 and is expected to exhibit a CAGR of 6.4% between 2021 and 2028.

What are the major factors driving the market growth?

Increasing incidence and prevalence of CH, development of novel therapeutics for the treatment of CH, and increasing global geriatric population are major driving factors for the market.

Which is the major type segment in the market?

Episodic is the major type segment in the market.

What are the key factors hampering growth of the market?

Insufficient awareness among healthcare providers and unfavorable healthcare policies negatively impacting overall healthcare spending are the major factors restraining growth of the market.

Which are the major players operating in the market?

Major players operating in the market include Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.